On June 18, Medtronic declined 3.51% in regular trading, trading at $78.335/share, with turnover of $299 million. The decline reflects a convergence of company-specific negatives and broad sector weakness in health care equipment.
On the company front, Medtronic faced multiple adverse developments: a major executive change on June 13, a U.S. recall of HVAD pump implant kits due to welding defects that caused one death and two injuries, and a loss in an intellectual property lawsuit against Xinwei Medical. These negatives compounded shortly after the company completed its $550 million acquisition of Scientia Vascular on June 12, which added guidewire and catheter capabilities to its neurovascular business.
Simultaneously, the Health Care Equipment sector experienced broad-based selling. Among top movers, Abbott Laboratories fell 2.34%, Boston Scientific dropped 3.08%, Intuitive Surgical declined 2.59%, and Stryker lost 3.05%, indicating clear sector-wide linkage effects weighing on the group.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments